Skip to main content
Diabetes Type 2 Diabetes

Type 2 Diabetes

16-07-2024 Obesity News

Greater weight loss with tirzepatide than semaglutide

Treatment with tirzepatide leads to greater weight loss than semaglutide in people with overweight or obesity, regardless of type 2 diabetes.

Editor's Choice

Managing lipids in diabetic kidney disease

Open Access Diabetic Nephropathy Review

People with diabetic kidney disease have an increased risk of cardiovascular disease but good lipid management can improve outcomes. Find out more with these practical recommendations.

Suboptimal CKD screening in people with type 2 diabetes

08-07-2024 Diabetic Nephropathy News

As many as three-quarters of US adults with type 2 diabetes are not being routinely screened for indicators of chronic kidney disease.

Fixed-ratio combinations for glycemic control

Open Access Diabetes Therapy Expert Opinion

How might fixed-ratio combinations of basal insulins and GLP-1 receptor agonists be used to optimize treatment of type 2 diabetes? Find out more in this expert opinion paper.

Managing type 2 diabetes and lower extremity PAD

Open Access Type 2 Diabetes Review

GLP-1 receptor agonists and SGLT2 inhibitors have demonstrated cardiovascular benefits, but where do they fit in the management of individuals who have type 2 diabetes and peripheral artery disease?

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Using CGM to optimize type 2 diabetes management with non-intensive insulin treatment in primary care

With the growing importance of primary care in diabetes, this podcast discusses the evidence on continuous glucose monitoring (CGM) use, the role of primary healthcare, and practical tips for interpreting the ambulatory glucose profile (AGP) report. 

Supported by: Abbott Diabetes Care

Prof. Samuel Seidu
Developed by: Adis

Case Studies

Abnormal glycated hemoglobin level in a patient with diabetes

Open Access Type 2 Diabetes Case Study

HbA1c levels that don’t match the clinical picture need further investigation. Other factors, such as Hb variants, can interfere with the HbA1c measurement and make glycemic control difficult to achieve.

Overlooked effect of angiotensin receptor–neprilysin inhibitor

Caution is needed when assessing insulin secretion capability and nephropathy in patients with diabetes who are being treated with an angiotensin receptor–neprilysin inhibitor.

DPP4 inhibitors a cause of IgG4-related kidney disease?

A man with type 2 diabetes and IgG4-related kidney disease developed bullous pemphigoid. DPP4 inhibitor treatment, which also correlated with changes in renal function, was discontinued.

Insulins Clinical Trial Summary

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.

Developed by: Springer Medicine

Current Reviews

Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group

Open Access Type 2 Diabetes Review

The increasing global incidence of obesity and type 2 diabetes mellitus (T2D) underscores the urgency of addressing these interconnected health challenges. Obesity enhances genetic and environmental influences on T2D, being not only a primary risk …

The Elusive Nature of ABCC8-related Maturity-Onset Diabetes of the Young (ABCC8-MODY). A Review of the Literature and Case Discussion

Maturity-Onset Diabetes of the Young (MODY) is an heterogenous group of monogenic forms of diabetes mellitus caused by genetic defects mainly leading to the secretory dysfunction of pancreatic β-cells [ 1 ]. MODY is a rare condition, accounting for …

Autophagy alterations in obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease: the evidence from human studies

Open Access Type 2 Diabetes CE-REVIEW

Autophagy is an evolutionarily conserved process that plays a pivotal role in the maintenance of cellular homeostasis and its impairment has been implicated in the pathogenesis of various metabolic diseases including obesity, type 2 diabetes …

Technology advances in diabetes pregnancy: right technology, right person, right time

Open Access Type 1 Diabetes Review

This review outlines some of the extraordinary recent advances in diabetes technology, which are transforming the management of type 1 diabetes before, during and after pregnancy. It highlights recent improvements associated with use of continuous …

Webinar | 08-11-2023 | 18:00 (CET)

Keynote webinar | Spotlight on diet and diabetes

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. Highlights include discussion of the recent EASD guidelines, therapeutic diets, food types and processing, plus psychological factors that influence patient success, and the drivers of healthy eating and diabetes control.

Prof. Mike Lean
Prof. Falko Sniehotta
Developed by: Springer Medicine

CME & eLearning

Videos | Case Scenarios | Infographics (Link opens in a new window)

1.0 AMA PRA Category 1 Credit(s)

Refine the application of CGM technology in primary care to enhance the management of type 2 diabetes. Benefit from key updates and experiential learning using CGM devices, and practice your clinical decision-making skills.

Supported by:
  • Abbott
Developed by: Springer Healthcare IME

Tweetorials | Vodcasts | Infographics (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)

Stay up to date with the rapidly changing CGM landscape. Learn how to implement and integrate CGM into diabetes management to improve patient care and outcomes.

Supported by:
  • Abbott
Developed by: Springer Healthcare IME

Vodcasts | Case Scenarios (Link opens in a new window)

Expert guidance on the multidisciplinary approach to identifying and managing chronic kidney disease in patients with type 2 diabetes, plus patient scenarios to assist your decision-making and put the latest clinical guidelines into context.

This program is not available to users in the UK and US.

Supported by:
  • Novo Nordisk A/S
Developed by: Springer Healthcare IME

Further Reading

Bone Fragility in High Fat Diet-induced Obesity is Partially Independent of Type 2 Diabetes in Mice

Open Access Type 2 Diabetes Original Research

Obesity and type 2 diabetes (T2D) are risk factors for fragility fractures. It is unknown whether this elevated risk is due to a diet favoring obesity or the diabetes that often occurs with obesity. Therefore, we hypothesized that the fracture …

ISIS 449884 Injection Add-On to Metformin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Study

Open Access Metformin Original Research

Diabetes mellitus (DM) is a collection of clinical syndromes characterized by an elevated blood glucose level. It results from a combination of genetic and environmental factors. The clinical symptoms of typical patients include polyuria …

Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6)

Open Access Tirzepatide Original Research

Type 2 diabetes (T2D) is characterised by insulin resistance and progressive loss of beta cell function [ 1 ]. Patients with long-standing inadequately controlled diabetes often require initiation of insulin therapy, usually with basal insulin.

Association of Changes in A1C Following Continuous Glucose Monitoring Acquisition in People with Sub-Optimally Treated Type 2 Diabetes Taking GLP-1 RA Therapy

Open Access Type 2 Diabetes Original Research

A target A1c of < 7% is the recommended goal for many people with type 2 diabetes (T2D) [ 1 ]; however, the National Committee for Quality Assurance has set A1c < 8% as their limit for control [ 2 ]. Nevertheless, many are not achieving either …